



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

symptoms, more rapid cessation of viral shedding, and fewer adverse events, including sinusitis, bronchitis, and nausea, were reported with baloxavir than with placebo. Most of these improved outcomes were seen in those who received their therapy within 0–36 h of symptoms being reported (rather than at timepoints after 36 h).

Despite the sound design and thorough conduct of the study, it has some limitations, such as the absence of immunosuppressed patients, pregnant women, and those with liver dysfunction. Additionally, there were few cases of influenza A H1N1 subgroup infections. However, the results of this study hold considerable promise for an efficacious, well-tolerated single-dose oral therapy for influenza, including in those at high risk of influenza complications.

I report being a paid consultant to various companies not involved in the production of antivirals (Melinta, Summit, Ferring).

Glenn S Tillotson

gtillotson@gstmicro.com

GST Micro, Richmond VA 23231, USA

1 Barry JM. *The Great Influenza*. New York City: Penguin Group, 2004: pp 5, 240.

- 2 Centers for Disease Control and Prevention. 2017–2018 estimated influenza illnesses, medical visits, hospitalizations, and deaths and estimated influenza illnesses, medical visits, hospitalizations, and deaths averted by vaccination in the United States. 2019. <https://www.cdc.gov/flu/about/burden-averted/2017-2018.htm> (accessed May 11, 2020).
- 3 Molinari N-A M, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. *Vaccine* 2007; **25**: 5086–96.
- 4 WHO. Influenza update—366. 2020. [https://www.who.int/influenza/surveillance\\_monitoring/updates/latest\\_update\\_GIP\\_surveillance/en/](https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/) (accessed May 4, 2020).
- 5 Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. *Curr Top Microbiol Immunol* 1992; **176**: 119–30.
- 6 Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients. *Arch Int Med* 2001; **161**: 212–17.
- 7 BioCryst Pharmaceuticals. 2014. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/206426lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206426lbl.pdf) (accessed May 11, 2020).
- 8 Centers for Disease Control and Prevention. What you should know about flu antiviral drugs. <https://www.cdc.gov/flu/treatment/whatyoushould.htm> (accessed May 4, 2020).
- 9 Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomized controlled trials. *Lancet* 2015; **385**: 1729–37.
- 10 Ison MG, Portsmouth S, Yoshida Y et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. *Lancet Infect Dis* 2020; published online June 8. [https://doi.org/10.1016/S1473-3099\(20\)30004-9](https://doi.org/10.1016/S1473-3099(20)30004-9).



## Persistence of US measles risk due to vaccine hesitancy and outbreaks abroad

Published Online  
July 30, 2020  
[https://doi.org/10.1016/S1473-3099\(20\)30522-3](https://doi.org/10.1016/S1473-3099(20)30522-3)

Results of a measles spatial risk analysis from May, 2019, published in *The Lancet Infectious Diseases*, identified US counties with the highest relative risk of a measles outbreak in 2019.<sup>1</sup> Measles outbreaks have persisted in the USA and globally with over 400 000 cases confirmed in 2019, reversing decades of progress towards measles elimination in many countries.<sup>2,3</sup> In the USA, 1282 cases of measles were reported in 2019 across 31 states and 94 counties, the most since 1992.<sup>4</sup>

In recent years, a growing vaccine hesitancy movement has contributed to decreasing vaccination rates in Europe and the USA.<sup>5</sup> In the USA, the national vaccination rate is 94.7%, representing good coverage on average.<sup>6</sup> However, even if a state has an average vaccination rate that is higher than the threshold for herd immunity, outbreaks can still occur if there exist localised communities with a high proportion of unvaccinated individuals. If such communities are highly connected by travel to regions experiencing large outbreaks, then risk of outbreaks in these communities is increased.

Decreasing vaccination rates, combined with an increase in measles outbreaks abroad and high volumes of international travel, places the USA at increased risk of measles introduction and local outbreaks. In response to these persistent risk factors, we expanded upon our previous work<sup>1</sup> to identify the set of US counties at highest risk of measles outbreaks. The risk to each county was computed with a multiplicative function of four factors: incidence rate of measles at travel origin, international air travel volume from each such origin to a US destination county, measles, mumps, and rubella (MMR) vaccination rates in the county, and county population. This study extends the previous study by using a spatial diffusion model to distribute arriving travellers to US counties near international airports (including counties without an airport), and a comprehensive county-level MMR vaccination rate dataset for 40 states. The final risk measure can be interpreted as the expected relative size of measles outbreak in each county.

Results from the model are illustrated in the figure in appendix 1, which shows the percentage of the population unvaccinated for measles in each US county, the location and relative size of the reported measles outbreaks in 2019, the location of the 20 most visited airports in the USA, and the 30 counties at highest risk of measles outbreaks. A detailed description of the data and methods is provided in appendix 2, and the complete set of results and input data are provided in appendix 3.

The results are spatially concordant with the counties that reported measles cases in 2019. Multiple regions in California, New York, Washington, Texas, and Florida are identified as being of highest risk of measles outbreaks, which is concordant with the 2019 outbreaks. Of the 20 highest ranked counties, 17 reported at least one measles case in 2019 and together reported over 700 of the 1276 confirmed cases in the USA. Model results indicate Los Angeles (CA), Seattle (WA), Honolulu (HI), Miami (FL), and Santa Ana (CA) to be the five counties at highest risk, with the Philippines, Samoa, Ukraine, New Zealand, and Israel as countries of highest risk for measles importation to the USA. The four air travel routes posing the highest risk of measles importation ended in Los Angeles and originated in the Philippines, Samoa, New Zealand, and Ukraine. The top 100 US counties and travel routes are listed in appendix 2.

This study has notable limitations. First, the risk model does not fully incorporate the risk of domestic spread within the USA; therefore, it underestimates the risk posed to counties that are highly connected through domestic travel to communities with outbreaks. Second, we use WHO confirmed, as opposed to suspected, cases of measles to estimate country case incidence, which underestimates the risk posed by countries with scarce resources for case confirmation. Third, the model is based on the cumulative number of measles cases reported in each country and total travel volume in 2019. Fourth, in response to the 2019 outbreaks, several countries substantially increased their vaccination rates

through immunisation programmes and are therefore less likely to experience a large future outbreak than before these initiatives; thus, the risk posed by these countries is probably overestimated. Fifth, the 2019 MMR rates that were used for this analysis do not account for recent policy changes and vaccination campaigns in New York, Maine, and Washington; consequently, the risk posed to these states is overestimated. Finally, the effect of COVID-19 on MMR rates in the USA and internationally are not represented. In response to COVID-19, vaccination rates in the USA and globally could drop because of a disruption in regular clinic visits or suspended vaccination programmes. Further, US counties at high risk in this study could represent high risk locations for future COVID-19 outbreaks, if they remain similarly resistant to a COVID-19 vaccine; however, changes in risk perception could increase vaccine uptake.

KK is the founder and CEO of BlueDot, a certified social benefit corporation that builds digital health solutions for infectious diseases. All other authors declare no competing interests.

\*Lauren Gardner, Ensheng Dong, Kamran Khan, Sahotra Sarkar  
l.gardner@jhu.edu

Department of Civil and Systems Engineering, Johns Hopkins University, Baltimore, MD 21218, USA (LG, ED); St. Michael's Hospital, Toronto, ON, Canada (KK); Department of Medicine, University of Toronto, Toronto, ON, Canada (KK); BlueDot, Toronto, ON, Canada (KK); and Department of Philosophy and Department of Integrative Biology, University of Texas, Austin, TX, USA (SS)

- 1 Sarkar S, Zlojutro A, Khan K, Gardner L. Measles resurgence in the USA: how international travel compounds vaccine resistance. *Lancet Infect Dis* 2019; **19**: 684–86.
- 2 WHO Europe. 2019. Measles and rubella surveillance data. [https://www.who.int/immunization/monitoring\\_surveillance/burden/vpd/surveillance\\_type/active/measles\\_monthlydata/en/](https://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/measles_monthlydata/en/) (accessed Dec 11, 2019).
- 3 US Department of Health and Human Services. Oct 4, 2019. With end of New York outbreak, United States keeps measles elimination status. <https://www.hhs.gov/about/news/2019/10/04/end-new-york-outbreak-united-states-keeps-measles-elimination-status.html> (accessed Jan 12, 2020).
- 4 US Centers for Disease Control and Prevention. Measles Cases and Outbreaks. <https://www.cdc.gov/measles/cases-outbreaks.html> (accessed May 1, 2020).
- 5 Olive JK, Hotez PJ, Damania A, Nolan MS. The state of the antivaccine movement in the United States: a focused examination of nonmedical exemptions in states and counties. *PLoS Med* 2018; **15**: e1002578.
- 6 Seither R, Loretan C, Driver K, Mellerson JL, Knighton CL, Black CL. Vaccination coverage for selected vaccines and exemption rates among children in kindergarten—United States, 2018–19 school year. *MMWR Morb Mortal Wkly Rep* 2019; **68**: 905–12.

See Online for appendix 1

See Online for appendix 2

See Online for appendix 3

## Long-term consequences of COVID-19: research needs

Weeks and months after the onset of acute COVID-19, people continue to suffer. Paul Garner, a professor of epidemiology at Liverpool School of Tropical Medicine,

UK, wrote on the 95th day after the onset of symptoms that “I am unable to be out of bed for more than three hours at a stretch, my arms and legs are permanently



Published Online  
September 1, 2020  
[https://doi.org/10.1016/S1473-3099\(20\)30701-5](https://doi.org/10.1016/S1473-3099(20)30701-5)